Lodise Thomas P, Patel Nimish, Kwa Andrea, Graves Jeffrey, Furuno Jon P, Graffunder Eileen, Lomaestro Ben, McGregor Jessina C
Albany College of Pharmacy, Pharmacy Practice, Albany College of Pharmacy, Albany, NY 12208-3492, USA.
Antimicrob Agents Chemother. 2007 Oct;51(10):3510-5. doi: 10.1128/AAC.00338-07. Epub 2007 Jul 23.
Although a growing number of studies have found a relationship between delayed appropriate antibiotic therapy and mortality, few have attempted to quantify the temporal association between delayed appropriate antibiotic therapy and mortality. This study was designed to measure the elapsed time associated with an increased risk of 30-day mortality among patients with Pseudomonas aeruginosa bacteremia. The retrospective cohort study was conducted among immunocompetent, adult patients with P. aeruginosa bacteremia onset at least 2 days after hospital admission between 1 January 2001 and 30 September 2006. Classification and regression tree analysis (CART) was used to identify the delay in appropriate antibiotic therapy that was associated with an increased risk of 30-day mortality. During the study period, 100 patients met the inclusion criteria. The CART-derived breakpoint between early and delayed treatment was 52 h. The delayed treatment group experienced a >2-fold significant increase in 30-day mortality compared to the early treatment group (44 and 19%, respectively, P = 0.008). Delayed appropriate therapy of >52 h (odds ratio [OR] = 4.1; 95% confidence interval [CI] 1.2 to 13.9, P = 0.03) was independently associated with 30-day mortality in the multivariate analysis. Antibiotic resistance > or =3 classes (adjusted OR [AOR] = 4.6; 95% CI = 1.9 to 11.2, P = 0.001) and chronic obstructive pulmonary disease (AOR = 5.4; 95% CI = 1.5 to 19.7, P = 0.01) were independently associated with delayed appropriate therapy of >52 h. The data strongly suggest that delaying appropriate therapy for approximately 2 days significantly increases the risk of 30-day mortality in patients with P. aeruginosa bloodstream infections.
尽管越来越多的研究发现延迟恰当的抗生素治疗与死亡率之间存在关联,但很少有研究尝试量化延迟恰当的抗生素治疗与死亡率之间的时间关联。本研究旨在测量铜绿假单胞菌血症患者30天死亡风险增加所对应的时间间隔。该回顾性队列研究在2001年1月1日至2006年9月30日期间入院至少2天后发生铜绿假单胞菌血症的免疫功能正常的成年患者中进行。采用分类与回归树分析(CART)来确定与30天死亡风险增加相关的恰当抗生素治疗延迟时间。在研究期间,100名患者符合纳入标准。CART得出的早期治疗与延迟治疗的分界点为52小时。与早期治疗组相比,延迟治疗组的30天死亡率显著增加了2倍多(分别为44%和19%,P = 0.008)。在多变量分析中,延迟恰当治疗>52小时(比值比[OR]=4.1;95%置信区间[CI]为1.2至13.9,P = 0.03)与30天死亡率独立相关。抗生素耐药≥3类(校正OR[AOR]=4.6;95%CI = 1.9至11.2,P = 0.001)和慢性阻塞性肺疾病(AOR = 5.4;95%CI = 1.5至19.7,P = 0.01)与延迟恰当治疗>52小时独立相关。数据强烈表明,将恰当治疗延迟约2天会显著增加铜绿假单胞菌血流感染患者30天的死亡风险。